Saturday 17 October 2026
Export OPK’s income statement to Excel — free account
OPKO Health, Inc.
OPK Healthcare Diagnostics & Research
OPKO Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.9 million, down 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 4.32%, EPS grew 94.7%, free cash flow grew 46.5% and total debt rose 6.37%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.53
0.08
−4.97%
Follow OPK
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.93 | 1.49 | 1.56 | 1.88 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(26.04) | (44.80) | (36.51) | (34.77) | |
P/B ratio |
0.96 | 0.72 | 0.75 | 0.92 | |
Price to Tangible BV |
5.03 | 3.83 | 3.54 | 4.21 | |
EV/Sales |
2.01 | 1.49 | 1.51 | 1.90 | |
EV/EBITDA |
28.07 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.56) | (5.31) | (5.15) | (6.19) | |
EV/FCF |
(8.21) | (4.71) | (4.58) | (5.50) | |
Quick Ratio |
2.56 | 2.84 | 3.13 | 3.01 | |
Current Ratio |
3.35 | 3.61 | 3.97 | 3.70 | |
Net Debt/EBITDA |
2.99 | (0.06) | 1.73 | (1.22) | |
Debt/Assets |
18.98% | 18.51% | 17.69% | 16.48% | |
Debt/Equity |
0.29 | 0.29 | 0.27 | 0.25 | |
Asset Turnover |
0.31 | 0.29 | 0.29 | 0.30 | |
Operating CF/Net income |
5.17 | 0.35 | 0.83 | (1.60) | |
Capex/Depreciation |
(0.13) | (0.08) | (0.11) | (0.14) | |
Interest Coverage |
(0.61) | (4.66) | (3.39) | 4.23 | |
Research and Development Expense of Revenue |
20.28% | 23.51% | 22.08% | 19.83% | |
Selling, General and Administrative Expense of Revenue |
32.35% | 39.14% | 34.03% | 35.47% | |
Intangible Assets out of Total Assets |
0.52 | 0.53 | 0.52 | 0.51 | |
Share Based Compensation of Revenue |
1.37% | 2.20% | 1.96% | 1.96% | |
Graham Net Nets |
(0.13) | (0.13) | (0.09) | (0.05) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.00%) | (23.68%) | (23.81%) | (15.48%) | |
Free Cash Flow Yield |
(12.69%) | (21.26%) | (21.19%) | (18.41%) | |
Revenue per Share |
0.22 | 0.16 | 0.20 | 0.20 | |
Operating CF per Share |
(0.06) | (0.03) | (0.03) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.06) | (0.03) | (0.04) | (0.05) | |
Cash per Share |
0.40 | 0.45 | 0.49 | 0.53 | |
Shareholders Equity per Share |
1.57 | 1.59 | 1.69 | 1.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.57 | 1.59 | 1.69 | 1.68 | |
Free Cash Flow |
(46.36) | (21.11) | (28.49) | (37.77) | |
Working Capital |
350.87 | 386.98 | 435.20 | 457.81 | |
Capital Expenditures |
(2.86) | (1.80) | (2.57) | (3.12) | |
Net Current Asset Value |
(145.05) | (116.82) | (82.10) | (62.89) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
90.63 | 87.89 | 104.14 | 100.58 | |
Average Payables |
53.36 | 51.77 | 44.09 | 56.77 | |
Average Inventory |
64.10 | 64.20 | 61.31 | 62.18 | |
Average Assets |
1,901.22 | 1,992.56 | 2,066.08 | 2,125.81 | |
Average Common Equity |
1,240.54 | 1,258.14 | 1,316.70 | 1,354.45 |
Columns are period end dates